Conjugation of melanotransferrin antibody on solid lipid nanoparticles for mediating brain cancer malignancy

Biotechnology Progress

Volumn 32, Issue 2, 2016, Pages 480-490

  Kuo, Yung Chih ^a   Chao, In Wei ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Blood brain barrier; Etoposide; Glioblastoma multiforme; Melanotransferrin; Solid lipid nanoparticle

Indexed keywords

ANTIBODIES; BLOOD; CELLS; CYTOLOGY; EFFICIENCY; LIPIDS; NANOPARTICLES; PARTICLE SIZE;

BLOOD-BRAIN BARRIER; ETOPOSIDE; GLIOBLASTOMA MULTIFORME; MELANOTRANSFERRIN; SOLID LIPID NANOPARTICLE (SLN);

ENDOTHELIAL CELLS;

LIPID; MELANOTRANSFERRIN PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NANOPARTICLE;

BREAST TUMOR; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; PARTICLE SIZE; PATHOLOGY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HUMANS; LIPIDS; MEMBRANE GLYCOPROTEINS; NANOPARTICLES; PARTICLE SIZE;

EID: 84953306294     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.2214     Document Type: Article

References (51)

1. Fujimaki T. Central nervous system germ cell tumors: classification, clinical features, and treatment with a historical overview. J. Child Neurol. 2009; 24:1439-1445.
2. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem. Pharmacol. 2010; 80:654-665.
3. Packer RJ, MacDonald T, Vezina G. Central nervous system tumors. Hematol. Oncol. Clin. North Am. 2010; 24:87-108.
4. Belda-Iniesta C, de Castro Carpeno J, Casado Saenz E, Cejas Guerrero P, Perona R, Gonzalez Baron M. Molecular biology of malignant gliomas. Clin. Transl. Oncol. 2006; 8:635-641.
5. Brown JP, Hewick RM, Hellstrom I, Hellstrom KE, Doolittle RF, Dreyer WJ. Human melanoma-associated antigen p97 is structurally and functionally related to transferring. Nature 1982; 296:171-173.
6. Rose TM, Plowman GD, Teplow DB, Dreyer WJ, Hellstrom KE, Brown JP. Primary structure of the human melanomaassociated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc. Natl. Acad. Sci. USA 1986; 83:1261-1265.
7. Kennard ML, Richardson DR, Gabathuler R, Ponka P, Jefferies WA. A novel iron uptake mechanism mediated by GPI anchored human p97. Embo J. 1995; 17:4178-4186.
8. Sekyere E, Richardson DR. The membrane-bound transferrin homologue melanotransferrin: roles other than iron transport? FEBS Lett. 2000; 483:11-16.
9. Rahmanto YS, Dunn LL, Richardson DR. The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark-from iron metabolism to tumorigenesis. Oncogene 2007; 26:6113-6124.
10. Rahmanto YS, Bal S, Loh KH, Yu Y, Richardson DR. Melanotransferrin: search for a function. Biochim. Biophys. Acta. 2012; 1820:237-243.
11. Rolland Y, Demeule M, Michaud-Levesque J, Beliveau R. Inhibition of tumor growth by a truncated and soluble form of melanotransferrin. Exp. Cell Res. 2007; 313:2910-2919.
12. Gordaliza M, Garcia PA, del Corral JM, Castro MA, Gomez-Zurita MA. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004; 44:441-459.
13. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 1998; 34:1514-1521.
14. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010; 17:421-433.
15. Needle MN, Molloy PT, Geyer JR, Herman-Liu A, Belasco BJ, Goldwein JW, Sutton L, Phillips PC. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med. Pediatr. Oncol. 1997; 29:28-32.
16. de Mendoza AE, Preat V, Mollinedo F, Blanco-Prieto MJ. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release 2011; 156:421-426.
17. Battaglia L, Gallarate M, Peira E, Chirio D, Solazzi I, Giordano SMA, Gigliotti CL, Riganti C, Dianzani C. Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies. Nanotechnology 2015; 26:255102
18. Martins S, Tho I, Reimold I, Fricker G, Souto E, Ferreira D, Brandl M. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int. J. Pharm. 2012; 439:49-62.
19. Carbone C, Campisi A, Manno D, Serra A, Spatuzza M, Musumeci T, Bonfanti R, Puglisi G. The critical role of didodecyldimethylammonium bromide onphysico-chemical, technological and biological properties of NLC. Colloids Surf. B 12014:1-10.
20. Carbone C, Campisi A, Musumeci T, Raciti G, Bonfanti R, Puglisi G. FA-loaded lipid drug delivery systems: Preparation, characterization and biological studies. Eur. J. Pharm. Sci. 2014; 52:12-20.
21. Kuo YC, Shih-Huang CY. Solid lipid nanoparticles with surface antibody for targeting the brain and inhibiting lymphatic phagocytosis. J. Taiwan Inst. Chem. Eng. 2014; 45:1154-1163.
22. Kuo YC, Lee CH. Inhibition against growth of glioblastoma multiforme in vitro using etoposide-loaded solid lipid nanoparticles with p-aminophenyl-α-D-manno-pyranoside and folic acid. J. Pharm. Sci. 2015; 104:1804-1814.
23. Kuo YC, Chen YC. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles. Int. J. Pharm. 2015; 479:138-149.
24. Kuo YC, Lu CH. Effect of human astrocytes on the characteristics of human brain-microvascular endothelial cells in the blood-brain barrier. Colloids Surf. B 2011; 86:225-231.
25. Kuo YC, Liang CT. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011; 32:3340-3350.
26. Kuo YC, Lu CH. Expression of P-glycoprotein and multidrug resistance-associated protein on human brain-microvascular endothelial cells with electromagnetic stimulation. Colloids Surf. B 2012; 91:57-62.
27. Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 2007; 340:143-152.
28. Kuo YC, Wang CC. Cationic solid lipid nanoparticles with cholesterol-mediated surface layer for transporting saquinavir to the brain. Biotechnol. Prog. 2014; 30:198-206.
29. Kuo YC, Ko HF. Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials 2013; 34:4818-4830.
30. Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009; 8:15
31. Chen CC, Tsai T, Huang Z, Fang J. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm. 2010; 74:474-482.
32. Shah M, Pathak K. Development and statistical sptimization of solid lipid nanoparticles of simvastatin by using full-factorial design. AAPS Pharm. Sci. Tech. 2010; 11:489-496.
33. Reddy LH, Murthy RSR. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS Pharm. Sci. Tech. 2005; 6:158-166.
34. Kuo YC, Yu HW. Surface coverage of didecyl dimethylammonium bromide on poly(lactide-co-glycolide) nanoparticles. Colloids Surf. B 2011; 84:253-258.
35. Kuntsche J, Horst JC, Bunjes H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int J. Pharm. 2011; 417:120-137.
36. Guy RH, Hadgraft J, Ketlaway IW, Taylor MJ. Calculations of drug release rates from spherical particles. Int. J. Pharm. 1982; 11:199-207.
37. Demeule M, Poirier J, Jodoin J, Bertrand Y, Desrosiers RR, Dagenais C, Nguyen T, Lanthier J, Gabathuler R, Kennard M, Jefferies WA, Karkan D, Tsai S, Fenart L, Cecchelli R, Beliveau R. High transcytosis of melanotransferrin (p97) across the blood-brain barrier. J. Neurochem. 2002; 83:924-933.
38. Karkan D, Pfeifer C, Vitalis TZ, Arthur G, Ujiie M, Chen Q, Tsai S, Koliatis G, Gabathuler R, Jefferies WA. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One 2008; 3:e2469
39. Tang Y, Han T, Everts M, Zhu ZB, Gillespie GY, Curiel DT, Wu H. Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Gene Therapy. 2007; 14:523-532.
40. Rolland Y, Demeule M, Fenart L, Beliveau R. Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface. Pigment Cell Melanoma Res. 2009; 22:86-98.
41. Kuo YC, Wang CC. Carmustine-loaded catanionic solid lipid nanoparticles with serotonergic 1B receptor subtype antagonist for in vitro targeted delivery to inhibit brain cancer growth. J. Taiwan Inst. Chem. Eng. 2015; 46:1-14.
42. Snehalatha M, Venugopal K, Saha RN, Babbar AK, Sharma RK. Etoposide loaded PLGA and PCL nanoparticles II: biodistribution and pharmacokinetics after radiolabeling with Tc-99m. Drug Deliv. 2008; 15:277-287.
43. Kuo YC, Lin CC. Rescuing apoptotic neurons from Alzheimer's disease using wheat germ agglutinin-conjugated and cardiolipin-conjugated liposomes with encapsulated neuron growth factor and curcumin. Int. J. Nanomed. 2015; 10:2653-2672.
44. Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev. 2009; 61:438-456.
45. Kim SB, Ozawa T, Tao H, Umezawa Y. A proinflammatory cytokine sensor cell for assaying inflammatory activities of nanoparticles. Anal. Biochem. 2007; 362:148-150.
46. Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol. Cancer Ther. 2006; 5:1474-1482.
47. Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomed. Nanotech. Biol. Med. 2013; 9:492-503.
48. Chirio D, Gallarate M, Peira E, Battaglia L, Muntoni E, Riganti C, Biasibetti E, Capucchio MT, Valazza A, Panciani P, Lanotte M, Annovazzi L, Caldera V, Mellai M, Filice G, Corona S, Schiffer D. Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. Eur. J. Pharm. Biopharm. 2014; 88:746-758.
49. Kusumoto K, Ishikawa T. Didodecyldimethylammonium bromide (DDAB) induces caspase-mediated apoptosis in human leukemia HL-60 cells. J. Control. Release 2010; 147:246-252.
50. Gabathuler R, Arthur G, Kennard M, Chen Q, Tsai S, Yang J, Schoorl W, Vitalis TZ, Jeffereies WA. Development of a potential protein vector (NeuroTrans) to deliver drugs across to the blood-brain barrier. Int. Congres. Series. 2005; 1277:171-184.
51. Rothenberger S, Food MR, Gabathuler R, Kennard ML, Yamada T, Yasuhara O, McGeer PL, Jefferies WA. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Brain Res. 1996; 712:117-121.